Lymph Node Staging in Lung Cancer Using [18F]FDG-PET

G. Halter; A. K. Buck; H. Schirrmeister; E. Aksoy; F. Liewald; G. Glatting; B. Neumaier; B. Mühling; K. Nüssle-Kügele; M. Hetzel; L. Sunder-Plassmann; S. N. Reske

doi:10.1055/s-2004-817844

The Thoracic and Cardiovascular Surgeon, Table of Contents

Thorac Cardiovasc Surg 2004; 52(2): 96-101
DOI: 10.1055/s-2004-817844

Original Thoracic

Lymph Node Staging in Lung Cancer Using [¹⁸F]FDG-PET

G. Halter¹ , A. K. Buck² , H. Schirrmeister² , E. Aksoy¹ , F. Liewald¹ , G. Glatting² , B. Neumaier² , B. Mühling¹ , K. Nüssle-Kügele⁴ , M. Hetzel³ , L. Sunder-Plassmann¹ , S. N. Reske²

¹Department of Thoracic and Vascular Surgery, University of Ulm, Ulm, Germany
²Department of Nuclear Medicine, University of Ulm, Ulm, Germany
³Department of Internal Medicine II, University of Ulm, Ulm, Germany
⁴Department of Radiology, University of Ulm, Ulm, Germany

Abstract

All articles of this category

Abstract

Background: Mediastinal lymph node staging is essential to determine treatment options in patients with NSCLC. Positron emission tomography (PET) detects increased glucose uptake in malignant tissue using the glucose analogue 2-[¹⁸F]fluoro-2-deoxy-D-glucose (FDG). Patients and Methods: In the present study were evaluated 155 patients with focal pulmonary tumors who underwent both preoperative computed tomography (CT) and FDG-PET scanning (116 malignant and 39 benign lesions). Results: Findings in 155 patients included 116 malignant and 39 benign lesions. For N-staging, FDG-PET showed a sensitivity of 88 %, a specificity of 91 %, and an accuracy of 89 %. Corresponding figures for CT were 77 %, 76 %, and 77 %, respectively. Conclusions: FDG-PET is an effective, noninvasive method for staging thoracic lymph nodes in patients with lung cancer and is superior to CT scanning in the assessment of hilar and mediastinal nodal metastases. With regard to operability, FDG-PET could differentiate reliable between patients with N1/N2 disease and those with unresectable N3 disease.

Key words

Lung cancer - lymph node staging - FDG-PET

Full Text

References

1 Mountain C F. Revisions in the international system for staging lung cancer. Chest. 1997; 111 1710-1717
2 Wittekind C H, Wagner (eds) G. UICC TNM-Klassifikation maligner Tumoren. Berlin, Heidelberg, New York; Springer 1997
3 Drings P, Vogt-Moykopf I. Thoraxtumoren. Heidelberg, New York; Springer 1998
4 Glazer G M, Gross B H, Quint L E, Francis I R, Bookstein F L, Orringer M B. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol. 1985; 144 261-265
5 McLoud T C, Bourgouin P M, Greenberg R W, Kosiuk J P, Templeton P A, Shepard J A. et al . Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992; 182 319-323
6 Dales R E, Stark R M, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. Am Rev Respir Dis. 1990; 141 1096-1101
7 Gallagher B M, Fowler J S, Gutterson N I, MacGregor R R, Wan C N, Wolf A P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18 F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978; 19 1154-1161
8 Schmidlin P. Iterative algorithms for emission tomography [in German]. Nuklearmedizin. 1990; 3 155-158
9 Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A. et al . A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994; 330 153-158
10 McKenna Jr R J, Libshitz H I, Mountain C E, McMurtrey M J. Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer. Chest. 1985; 88 206-210
11 Staples C A, Muller N L, Miller R R, Evans K G, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology. 1988; 167 367-372
12 Kauczor H U, Kreitner K F. Contrast-enhanced MRI of the lung. Eur J Radiol. 2000; 34 196-207
13 [No authors listed]. Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med. 1997; 156 320-332
14 Luke W P, Pearson F G, Todd T R, Patterson G A, Cooper J D. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg. 1986; 91 53-56
15 De Leyn P, Vansteenkiste J, Cuypers P, Deneffe G, Van Raemdonck D, Coosemans W. et al . Role of cervical mediastinoscopy in staging of non-small-cell lung cancer without enlarged mediastinal lymph nodes on CT scan. Eur J Cardiothorac Surg. 1997; 12 706-712
16 Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske S N. Lymph node staging in non-small cell lung cancer: evaluation by [18 F]FDG positron emission tomography (PET). Thorax. 1997; 52 438-441
17 Kalff V, Hicks R J, MacManus M P, Binns D S, McKenzie A F, Ware R E. et al . clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001; 19 111-118
18 Liewald F, Grosse S, Storck M, Guhlmann A, Halter G, Reske S. et al . How useful is positron emission tomography for lymph node staging in non-small-cell lung cancer?. Thorac Cardiovasc Surg. 2000; 48 93-96
19 Scott W J, Schwabe J L, Gupta N C, Dewan N A, Reeb S D, Sugimoto J T. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18 F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg. 1994; 58 698-703
20 Shon I H, O'Doherty M J, Maisey M N. Positron emission tomography in lung cancer. Semin Nucl Med. 2002; 32 240-271
21 Vansteenkiste J F, Stroobants S G, De Leyn P R, Dupont P J, Bogaert J, Maes A. et al . Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998; 16 2142-2149
22 Pieterman R M, van Putten J W, Meuzelaar J J, Mooyaart E L, Vaalburg W, Koeter G H. et al . Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000; 343 254-261
23 Patz Jr E F, Lowe V J, Goodman P C, Herndon J. Thoracic nodal staging with PET imaging with 18 FDG in patients with bronchogenic carcinoma. Chest. 1995; 108 1617-1621
24 Berlangieri S U, Scott A M, Knight S R, Fitt G J, Hennessy O F, Tochon-Danguy H J. et al . F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg. 1999; 16 (Suppl 1) S25-30
25 Gupta N C, Graeber G M, Bishop H A. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (> 3 cm) lymph node lesions. Chest. 2000; 117 773-778
26 Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach K W, Schicha H. Cost-effectiveness of FDG-PET for the management of potentially operable non-small-cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000; 27 1598-1609
27 Lardinois D, Weder W, Hany T F, Kamel E M, Korom S, Seifert B, von Schulthess G K, Steinert H C. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003; 348 2500-2507

Dr. med. Gisela Halter

Department of Thoracic and Vascular Surgery
University of Ulm

Steinhövelstraße 9

89075 Ulm

Germany

Email: gisela.halter@medizin.uni-ulm.de